Alterations in plasminogen activator and inhibitor activity during the differentiation of a human neuroblastoma cell line, SMS-KAN.
The fibrinolytic enzyme profile of SMS-KAN human neuroblastoma cells was found to vary dramatically during the differentiation process. Five maturational agents--retinoic acid, dibutyryl cAMP, 5-bromodeoxyuridine, sodium butyrate and phorbol myristate acetate were tested for their effects on cellular morphology, DNA synthesis, plasminogen activator (PA) and PA inhibitor (PAI) activity. SMS-KAN cells secrete urokinase (UK) and tissue PA (tPA) as well as a possibly unique PAI. Treatment of cells with 1 microM RA resulted in an inhibition of proliferation, extension of neurite-like processes indicative of differentiation, as well as a switch from secretion of UK to tPA and a reduction in PAI secretion. Other agents which caused neural process formation and decreased cell proliferation also induced alterations in PA/PAI while agents which had no detectable effect on cell growth induced little change in the fibrinolytic enzyme profile.
Benjamin
L A
LA
Department of Pediatrics, University of Calgary, Alberta, Canada.
McGarry
R C
RC
Hart
D A
DA
D001973:Bromodeoxyuridine / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002454:Cell Differentiation; D002460:Cell Line; D004261:DNA Replication / Q000187:drug effects; D005342:Fibrinolysis; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D009447:Neuroblastoma / Q000032:analysis*; D010960:Plasminogen Activators / Q000032:analysis*; D015849:Plasminogen Inactivators; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology
D002087:Butyrates; D006023:Glycoproteins; D015849:Plasminogen Inactivators; D020148:Butyric Acid; D014212:Tretinoin; D003994:Bucladesine; D010960:Plasminogen Activators; D001973:Bromodeoxyuridine; D013755:Tetradecanoylphorbol Acetate